Compare Gilead Sciences, Inc. (GILD) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Abrdn Physical Platinum Shares ETF — how do they compare? Gilead Sciences, Inc. trades at $148.6 (market cap $182.40B), while Abrdn Physical Platinum Shares ETF trades at $15.23 (market cap $1.93B). The key difference: Gilead Sciences, Inc. is far larger — about 94.5× Abrdn Physical Platinum Shares ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Abrdn Physical Platinum Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Abrdn Physical Platinum Shares ETF for 42 Days on average.
| GILD | PPLT | |
|---|---|---|
Market Cap | $182.40B | $1.93B |
Volume | 4,469,821 | 1,698,523 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $155.80 | $25.23 |
52-Week Low | $116.74 | $13.73 |
Typical Hold Time | 111 Days | 42 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
PPLT, the abrdn Physical Platinum Shares ETF, trades at $14.78, down 4.46% today, reflecting a bearish technical outlook with moving averages and oscillators signaling sell pressure. Recent news highlights platinum's underperformance versus other precious metals, with the term structure in contango suggesting adequate supply. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook remains cautious due to weak technical signals and platinum's lag in the metals rally, though historical seasonality may offer contrarian hope. Risks include commodity price volatility and supply-demand dynamics. Investors should await updated financials for a clearer fundamental picture amid current bearish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
